公司简介
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C...
关联新闻
- Zura Bio's skin disease drug fails mid-stage trial
Zura Bio said on Monday its experimental drug failed the main goal of a mid-stage study in patients with hidradenitis suppurativa, a chronic skin disease that causes painful lumps under the skin.